Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics

Jurre den Haan 1*, Tjado H. J. Morrema 2, Annemieke J. Rozemuller 2, Femke H. Bouwman 1 and Jeroen J. M. Hoozemans 2

Abstract

The combined fluorescent and Aβ-binding properties of the dietary spice curcumin could yield diagnostic purpose in the search for a non-invasive Aβ-biomarker for Alzheimer’s disease (AD). However, evidence on the binding properties of curcumin, its conjugates and clinically used bio-available formulations to AD neuropathological hallmarks is scarce. We therefore assessed the binding properties of different curcumin forms to different neuropathological deposits in post-mortem brain tissue of cases with AD, other neurodegenerative diseases, and controls. Post mortem brain tissue was histochemically assessed for the binding of curcumin, its isoforms, conjugates and bio-available forms and compared to routinely used staining methods. For this study we included brains of early onset AD, late onset AD, primary age-related tauopathy (PART), cerebral amyloid angiopathy (CAA), frontotemporal lobar degeneration (FTLD) with tau or TAR DNA-binding protein 43 (TDP-43) inclusions, dementia with Lewy bodies (DLB), Parkinson’s disease (PD) and control cases without brain pathology. We found that curcumin binds to fibrillar amyloid beta (Aβ) in plaques and CAA. It does not specifically bind to inclusions of protein aggregates in FTLD-tau cases, TDP-43, or Lewy bodies. Curcumin isoforms, conjugates and bio-available forms show affinity for the same Aβ structures. Curcumin staining overlaps with immunohistochemical detection of Aβ in fibrillar plaques and CAA, and to a lesser extent cored plaques. A weak staining of neurofibrillary tangles was observed, while other structures immunopositive for phosphorylated tau remained negative. In conclusion, curcumin, being a food additive with fluorescent properties, is therefore an interesting candidate for in-vivo diagnostics in AD, for example in retinal fluorescent imaging.

Keywords: Curcumin, Amyloid-beta, Alzheimer’s disease, Cerebral amyloid angiopathy (CAA), Neurodegeneration, Biomarker, Immunohistochemistry

Introduction

Aggregation and extracellular deposition of the amyloid-beta (Aβ) peptide in amyloid plaques is a pathological hallmark and an early event in the pathophysiology of Alzheimer’s disease (AD) [4,18]. Currently AD diagnosis can be made with help of clinical criteria with the support of measurements of Aβ1–42 and tau181 in cerebrospinal fluid (CSF), amyloid-positron emission tomography (PET), cortical atrophy on magnetic resonance imaging (MRI), or hypo-metabolism by fluorodeoxyglucose–PET (FDG-PET) [35]. As these are all either invasive or time consuming investigations, a patient friendly and repeatable amyloid or Aβ biomarker is urgently needed for diagnosis as well as therapy monitoring in clinical trials [15]. Curcumin is a dietary spice that has been shown to have combined fluorescent and Aβ-binding properties [16, 37, 39]. Therefore, curcumin has the potential to...
be used as a tool in a non-invasive Aβ-directed diagnostic assay for AD. A recently published paper by Koronyo et al. shows possible application of curcumin for in-vivo detection of retinal amyloid [22].

Curcumin is a polyphenolic compound derived from the root Curcuma longa or turmeric, traditionally used in Indian cuisine and Ayurvedic medicine. Turmeric naturally contains three curcuminoids namely; curcumin (≈77%), demethoxycurcumin (DMC) (≈17%) and bis-demethoxycurcumin (BDMC) (≈3%) [10]. Curcumin is fluorescent by nature [16, 37]. It has anti-carcinogenic, anti-inflammatory, anti-oxidant and anti-angiogenic properties and binds to Aβ and interferes with Aβ aggregation [10, 28]. More specifically curcumin binds Aβ-oligomers and fibrils in vitro [41, 52], binds plaques in APPSWE/PS1ΔE9, Tg2576 and 5xFAD transgenic mice [23, 29, 30, 53] and binds Aβ-plaques in post mortem human AD brain tissue [23, 39, 49, 53]. Two reports also described moderate binding of curcumin to neurofibrillary tangles in AD brain tissue [36, 39].

In order to apply curcumin as a tool for in-vivo detection of Aβ its poor bio-availability and in-vivo metabolism should be considered. The majority (35–89%) of the orally administered curcumin is present in the feces, as the intestinal mucosa and mucus form a physical barrier [14, 43]. Secondly, that curcumin does reach the circulation undergoes phase 1 (reduction) and phase 2 metabolism (conjugation) in the liver. Reductases reduce curcumin to dicydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin etc. [31, 32, 42]. In addition, curcumin is conjugated to sulfates and glucuronides [5, 17, 31, 32]. Therefore, the majority of circulating curcumin is conjugated. To overcome curcumin’s poor bio-availability, nano-particulate drug delivery systems have been developed for oral administration including micelles, solid lipid nanoparticles and liposomes (Theracurmin™ [20, 40, 44], Novasol™ [7, 21, 45], Longvida™ [11, 22]).

So far, there are no reports on the Aβ-binding properties of conjugated curcumin or bio-available forms of curcumin. Insight into binding properties of circulating curcuminoids in the blood (e.g. DMC, BDMC, and curcumin conjugates) and specific bio-available formulations is needed for the design of biomarker assays using oral (bio-available) curcumin formulations. In this study, we assessed the binding properties of curcumin, its isoforms, its conjugates and clinically used bioavailable curcumin supplements to neuropathological hallmarks of AD and other neurodegenerative features in post mortem brain tissue.

Materials and methods

Post mortem brain tissue

Post mortem brain tissue was obtained from the Netherlands Brain Bank (NBB; Amsterdam, the Netherlands). Prior to death, donors signed informed consent for brain autopsy and use of brain tissue and medical records for research purposes. For this study we selected 5 early onset AD (EOAD)-patients, 5 late onset AD (LOAD) patients, 5 AD cases with capillary cerebral amyloid angiopathy (CAA type-1), 5 controls, 5 cases with primary age related tauopathy (PART), 3 frontotemporal lobar degeneration (FTLD) cases with tau pathology (FTLD-tau), 1 FTLD case with TDP-43 pathology (FTLD-TDP), 2 Parkinson’s disease (PD) cases and 1 dementia with Lewy bodies (DLB) case who donated their brains to the NBB between 2000 and 2014. EOAD cases had a reported disease onset before 65 years of age (mean age of death 61.6 years), while LOAD cases had reported disease onset > 65 years. Neuropathological diagnosis of AD was made following the NIA-AA criteria including Thal-staging for Aβ stage, Braak-and Braak-staging for NFTs and CERAD-staging for neuritic plaques [1, 38, 48]. Pathological diagnosis of CAA-type 1, FTLD (tau and TDP-43), DLB and PD were made following Thal-, Mackenzie-, McKeith- and Braak-staging criteria respectively [2, 25–27, 33, 34, 47]. Two of the FTLD-Tau cases were P301L mutations (chromosome 17), while one was a sporadic Pick’s disease case. The FTLD-TDP43 case was a progranulin mutation. See Table 1 for cohort characteristics.

Immunohistochemistry (IHC)

For each case we assessed formalin-fixed paraffin-embedded tissue sections (5 μm thick) from mesencephalon, hippocampus, frontal or occipital lobes. Paraffin-embedded tissue sections were deparaffinized and rehydrated using xylene, alcohol and phosphate-buffered saline (PBS; pH 7.4). Endogenous peroxidase activity was blocked by 0.3% H2O2-treatment of the sections. Heat induced antigen retrieval was performed in 0.01 M citrate buffer pH 6.0 using an autoclave. Sections were incubated overnight with primary antibody and subsequently washed with PBS (see details in Table 2). Primary antibodies were detected using EnVision (Dako, Glostrup, Denmark) followed by washing in PBS. Antibody complex binding was visualized using 3,3’-diaminobenzidine (DAB) and sections were counterstained with hematoxylin. Stained sections were covered using Quick-D (Klinipath, Beek, the Netherlands).

Thioflavin-S staining

Thioflavin-S staining was performed by incubating deparaffinized and rehydrated sections with 1% thioflavin-S (Sigma-Aldrich) solution (deionized water) for 1 min, followed by rinsing off excess thioflavin-S using 70% alcohol. Following staining slides were washed using PBS and covered using Tris-buffered saline (TBS)/glycercol mounting medium.
### Table 1 Cohort characteristics

| # | PM delay (h:min) | Pathological diagnosis (mutation) | Sex | Age | Braak | Amyloid |
|---|-----------------|-----------------------------------|-----|-----|-------|---------|
| 1 | 6:35            | Control                           | F   | 92  | III   | 0       |
| 2 | 7:10            | Control                           | F   | 78  | I     | A       |
| 3 | 4:35            | Control                           | F   | 78  | II    | A       |
| 4 | 7:15            | Control                           | M   | 95  | II    | B       |
| 5 | 5:15            | Control                           | M   | 83  | I     | A       |
| 6 | 5:00            | EOAD                              | M   | 61  | VI    | C       |
| 7 | 5:05            | EOAD                              | M   | 59  | VI    | C       |
| 8 | 4:40            | EOAD                              | M   | 62  | V     | B       |
| 9 | 4:45            | EOAD                              | M   | 64  | V     | C       |
| 10| 5:15            | EOAD                              | M   | 62  | VI    | C       |
| 11| 5:30            | LOAD                              | M   | 88  | VI    | C       |
| 12| 7:00            | LOAD                              | F   | 92  | V     | C       |
| 13| 4:40            | LOAD                              | F   | 89  | V     | C       |
| 14| 6:25            | LOAD                              | F   | 91  | IV    | C       |
| 15| 3:05            | LOAD                              | M   | 74  | VI    | C       |
| 16| 6:05            | CAA type 1                        | M   | 68  | II    | C       |
| 17| 4:20            | CAA type 1                        | M   | 81  | V     | C       |
| 18| 4:20            | CAA type 1                        | F   | 96  | V     | C       |
| 19| 3:25            | CAA type 1                        | M   | 94  | V     | C       |
| 20| 6:00            | CAA type 1                        | F   | 75  | V     | C       |
| 21| 5:30            | PART                              | F   | 81  | II    | 0       |
| 22| 3:52            | PART                              | F   | 89  | III   | 0       |
| 23| 5:00            | PART                              | F   | 87  | II    | 0       |
| 24| 5:50            | PART                              | F   | 93  | II    | 0       |
| 25| 6:35            | PART                              | F   | 103 | IV    | 0       |
| 26| 3:35            | FTLD-TDP (Progranulin)            | F   | 76  | n.a.  | A       |
| 27| 5:23            | FTLD-Tau (P301L)                  | M   | 60  | n.a.  | 0       |
| 28| 6:25            | FTLD-Tau (P301L)                  | M   | 64  | n.a.  | 0       |
| 29| 6:15            | FTLD-Tau (PID)                    | M   | 60  | n.a.  | 0       |
| 30| 24:00           | PD                                | M   | 57  | I     | 0       |
| 31| 33:00           | LBD/AD                            | F   | 78  | VI    | B       |
| 32| 14:00           | PD                                | M   | 68  | I     | 0       |

Abbreviations: CAA type 1 capillary cerebral amyloid angiopathy type 1, EOAD early onset Alzheimer’s disease, FTLD-tau frontotemporal lobar degeneration with tau pathology, FTLD-TDP-43 frontotemporal lobar degeneration with TDP-43 pathology, LOAD late onset Alzheimer’s disease, n.a. not applicable, PART primary age-related tauopathy, PiD Pick’s disease, PM delay post-mortem delay and PD Parkinson’s disease.

### Table 2 Primary antibodies used for immunohistochemistry and fluorescent staining

| Antibody | Source | Species | Dilution |
|----------|--------|---------|----------|
| IC-16    | Carsten Korth, Heinrich Heine University Dusseldorf, Düsseldorf, Germany [50] | Mouse | 1:400    |
| 4G8      | Biolegend, San Diego, CA, USA | Mouse | 1:8000   |
| AT8      | Invitrogen, Thermo Fisher Scientific, MA, USA | Mouse | 1:8000   |
| pTDP-43  | Cosmo Bio, Tokyo, Japan | Mouse | 1:8000   |
| LB-509   | Zymed, Thermo Fisher Scientific, MA, USA | Mouse | 1:200    |
Curcuminoid staining
Curcuminoids, conjugates and bio-available forms of curcumin were dissolved in 0.5 M NaOH to a stock concentration of 20 mg/ml (see details in Table 3). Final concentrations of 0.2, 0.1 and 0.05 mg/ml were prepared by dilution in PBS. Deparaffinized and rehydrated sections were incubated with curcumin solutions for 10 min, followed by washing in PBS. Stained sections were covered using TBS/glycerol mounting medium.

Combined curcumin staining and immunohistochemistry
Sections were deparaffinized and rehydrated, followed by blocking of endogenous peroxidase and antigen retrieval as described above. Subsequently, curcumin staining was performed, sections were washed in PBS, and immunohistochemistry was performed using anti-phosphorylated tau (anti-pTau, AT8,1:800) and anti-Aβ (IC-16, 1:400). Incubation was performed overnight, followed by washing in PBS. Secondary fluorescently labeled antibody (Goat Anti-mouse 594, Life Tech, 1:250) was incubated for 1.5 h, followed by washing in PBS. Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and covered with TBS/Glycerol.

Imaging
IHC sections were imaged by an Olympus BX41 microscope using Leica Application Suite (LAS) AF lite software (Wetzlar, Germany). Fluorescently stained slides were imaged by a Leica DMI8 fluorescence microscope.

| Group              | Curcumin-type                  | Source                                                                 | Molecule formula                        |
|--------------------|--------------------------------|------------------------------------------------------------------------|-----------------------------------------|
| Curcuminoids       | Turmeric (from grounded turmeric root, TRS wholesale, Southall, Middlesex, England) | Not applicable | |
|                    | Curcumin                       | Sigma Aldrich                                                          | Not applicable | |
|                    | Demethoxycurcumin (DMC)        | Sigma Aldrich                                                          | Not applicable | |
|                    | bis-Demethoxycurcumin (BDMC)   | Sigma Aldrich                                                          | Not applicable | |
| Conjugates         | Curcumin-sulfate               | TLC Pharmaceutical Standards Ltd                                       | Not applicable | |
|                    | Curcumin-glucuronide           | TLC Pharmaceutical Standards Ltd                                       | Not applicable | |
| Bio-available formulations | Theracurmin 60mg (60mg of Curcumin, DMC and BDMC) | Natural Factors                                                        | Not applicable | |
|                    | Novasol 50mg (82% curcumin, 16% DMC, 2% BDMC) | Aquanova                                                              | Not applicable | |
|                    | Longvida 500mg (min. 20% curcuminoids) | Verdure Sciences Inc.                                                   | Not applicable | |
using LAS AF lite and ImageJ software (National Institute of Health, USA).

**Results**

**Curcumin binding in control and AD brain tissue**

In general, it was observed that curcumin binding on human brain tissue presented no background staining and auto-fluorescent signals in neurons. In brain tissue of EOAD, LOAD and AD cases with CAA (CAA type 1), curcumin strongly bound to amyloid plaques and CAA (Fig. 1). Curcumin staining revealed different types of plaques. We observed intense staining of primitive/compact plaques and moderate staining of the cores in cored plaques. In AD cases, neurofibrillary tangles (NFTs) showed a weak detection by curcumin. Adjacent sections were assessed by immunohistochemistry for the presence of Aβ and pTau in a corresponding area, which confirmed the presence of these pathological structures.

The binding of curcumin to these pathological structures was investigated by co-stainings for curcumin and Aβ (IC-16) or pTau (AT8). Primitive/compact plaques showed almost a complete overlap of curcumin signal and immunodetection by Aβ (Fig. 2). Classic cored plaques presented co-labeling of the core, while the corona of these plaques were immuno-labelled by anti-Aβ and not by curcumin. No binding of curcumin was observed in diffuse Aβ deposits. CAA affected blood vessels were stained most intensively by curcumin and showed a complete overlap with the detection of CAA by Aβ. While compact plaques showed moderate neuritic changes, as presented by anti-pTau immuno-labeling, no co-labelling of anti-pTau and curcumin was present in these plaques (Fig. 3). Neuritic cored plaques showed a strong immunodetection of pTau around the core. The core of neuritic plaques showed a strong binding of curcumin while co-labelling with anti-pTau was absent. A strong

---

**Fig. 1** Detection of AD pathological hallmarks using curcumin. Curcumin staining of AD pathological hallmarks in early and late onset AD cases and AD cases with CAA type 1 (CAA-1) (a–d). Immunohistochemical DAB stainings for amyloid-beta (4G8 and IC-16) (e–l) and phosphorylated tau (AT8) (m–p) are shown for reference. Hippocampal blocks were used for AD-cases, while occipital blocks were used for CAA cases. IHC and fluorescent stainings were performed on the same brain region. Scale bars 100 μm. * = plaque, † = neurofibrillary tangle, ‡ = cerebral amyloid angiopathy. Abbreviations: EOAD = early onset Alzheimer’s disease, LOAD = late onset Alzheimer’s disease.
binding of curcumin was observed in CAA, however, no co-labelling with anti-pTau, observed around CAA affected capillaries, was detected. Co-labeling with anti-pTau confirmed that curcumin weakly detects NFTs. 

**Curcumin does not bind to non-AD pathology**

We investigated whether curcumin showed binding to protein inclusions or aggregates in non-AD pathologies. PART is characterized by the presence of NFTs and tau pathology in the absence of amyloid deposits [8, 19]. In cases with PART no specific binding of curcumin was observed. Co-labeling and single IHC with anti-pTau confirmed the presence of tau pathology and NFTs in the tissue section. In PART no binding of curcumin to NFTs was observed. Next, we assessed the binding of curcumin to tau inclusions in different FTLD-tau cases. Inclusions that were positive for pTau in cases with a MAPT P301L mutation, or in a case with sporadic...
Pick's disease, did not show binding of curcumin. Also inclusions positive for TDP-43 in FTLD-TDP, and α-synuclein containing inclusions in PD and DLB were not detected by curcumin (Fig. 4).

**Staining of curcumin isoforms, conjugates and bio-available forms**

In order to translate above findings to a possible in-vivo biomarker assay we assessed binding properties of different curcuminoids (DMC, BDMC), conjugates, and bio-available forms in AD cases. Given curcumin's chemical similarities with Thioflavin, sharing an aromatic ring, we compared stainings to Thioflavin-S staining (Fig. 5). An overview of staining of different curcumin forms and Thioflavin-S to plaques, CAA and NFTs is given in Table 4.

First, as turmeric also contains two isoforms: DMC (≈17%) and BDMC (≈3%), we assessed their binding. Similar to Thioflavin-S and curcumin, both isoforms bound amyloid plaques and CAA and showed weak

---

| Curcumin | pTau | Curcumin / pTau / DAPI |
|----------|------|------------------------|
| Compact plaques | | |
| Neuritic plaques | | |
| CAA | | |
| Neurofibrillary Tangles | | |

Fig. 3 Co-labelling using curcumin and anti-phosphorylated Tau in Alzheimer brains. Curcumin co-labelling with anti-phosphorylated tau using AT8 in Alzheimer brains (hippocampus(a-c), temporal cortex(d-f and j-l), occipital cortex(g-i)) to show overlap and differences. Scale bars A-I 100 μm. Scale bars J-L 50 μm. Abbreviations: CAA = cerebral amyloid angiopathy, DAPI = 4',6-diamidino-2-phenylindole
Fig. 4 Curcumin binding in non-AD pathologies. Curcumin staining of PART, FTLD-tau, FTLD-TDP-43, and PD cases (a-e). Fluorescent co-stainings for comparison of curcumin and tau (FTLD-tau), TDP-43 (FTD-TDP-43), and α-synuclein (PD) (f-j). Immunohistochemical DAB stainings for tau (AT8), TDP-43 (pTDP-43) and α-synuclein (LB-509) are shown for reference (k-o). Scale bars a-j 50 μm. Scale bars k-o 100 μm. Abbreviations: DAPI = 4′,6-diamidino-2-phenylindole, FTLD-tau = frontotemporal lobe degeneration with tau pathology, FTLD-TDP-43 = frontotemporal lobe degeneration with TDP-43 pathology, PART = primary age related tauopathy

Fig. 5 Staining of different curcumin forms to amyloid plaques, neurofibrillary tangles and CAA. Staining of amyloid-beta plaques, neurofibrillary tangles and CAA with Thioflavin-S and curcuminoids (a), conjugates (b) and bio-available forms (c). Scale bars 100 μm
staining of NFTs (Fig. 5a). Compared to Thioflavin-S, staining of fibrillar and primitive plaques by isoforms was slightly less apparent (Table 4).

Next, we assessed binding properties of curcumin conjugates (glucuronides, sulfates). As, curcumin is conjugated by the liver to make it water soluble, conjugates represent the majority of circulating curcuminoids. Curcumin-glucuronide and curcumin-sulfate bound to amyloid plaques and CAA (Fig. 5b). Curcumin glucuronide showed slightly less apparent staining of fibrillar, primitive/compact plaques and NFTs compared to Thioflavin-S (Table 4).

Finally, in order to translate above findings to clinically used oral bio-available formulations of curcumin we compared three bio-available formulations, namely Theracurmin, Novasol and Longvida. All three forms showed staining of primitive/compact plaques, the core of cored plaques, CAA and faintly stain NFTs, similar to Thioflavin-S (Table 4, Fig. 5c).

### Discussion

This study demonstrates that curcumin, curcuminoids, curcumin conjugates and bio-available formulations containing curcumin, bind to fibrillar amyloid in primitive/compact plaques, cored plaques and CAA in AD brain tissue. Curcumin isoforms and conjugates show few selective binding to NFTs in AD brain tissue and no binding to other neuropathological deposits, e.g. pTau and TDP-43 positive structures in FTLD and alpha-synuclein inclusions in PD and DLB. To the best of our knowledge we are the first to report that curcumin isoforms, conjugates and bio-available forms have similar staining properties as curcumin.

Comparing plaque types, binding of curcumin was more pronounced to amyloid deposits with a dense amyloid structure, as shown in Fig. 2 and Table 4. This is supported by co detection of curcumin with amyloid-beta in compact plaques while in contrast, diffuse plaques showed a lack of co-detection (Fig. 3).
indicates that curcumin binds preferably to dense amyloid structures, such as fibrillar plaques, rather than the amyloid beta peptide itself. The detection of amyloid by curcumin is comparable to the detection of amyloid by Thioflavin-S. This could be explained by the fact that curcumin and Thioflavin have chemical similarities, sharing a double aromatic ring [52].

Previous studies showed that curcumin binds Aβ-oligomers and fibrils in vitro [33, 44], Aβ-plaques in APPSWE/PS1ΔE9, Tg2576 and 5xFAD transgenic mice [19, 24, 30, 45] and in post mortem human AD brain tissue [19, 31, 41, 45]. The latter human studies however assessed relatively small patient cohorts and did not assess other neurodegenerative diseases. Our findings in a well-characterized and large cohort of cases confirm earlier findings of specific binding of curcumin to fibrillar Aβ plaques, weak binding to NFT's and rule out binding to pathological protein aggregates in other neurodegenerative diseases. Binding to fibrillar plaques might be of clinical relevance, as an increase of fibrillar plaques is associated with clinical progression to dementia [6]. In addition to curcumin binding to amyloid plaques, Mutsuga et al. described curcumin staining to CAA in larger vessels of an AD case as well as in various animals [39]. CAA can be subdivided in CAA type 1 (CAA-1) and CAA type 2 (CAA-2) [47]. CAA-1 is characterized by Aβ presence in leptomeningeal and cortical arteries, arterioles, veins and venules as well as cortical capillaries, while CAA-2 on the other hand, affects leptomeningeal and cortical vessels with the exception of capillaries. In addition to earlier findings in CAA-2 by Mutsuga et al. we showed that curcumin also binds to CAA in capillaries in CAA-1 cases [39].

To the existing literature we added the comparison of the binding properties of different curcumin forms in human brain tissue, which is needed to translate findings for possible use in in-vivo diagnostic or therapeutic studies. The majority of curcumin and its isoforms are conjugated in-vivo and conjugated curcumin represents a large proportion of circulating curcumin [12]. To overcome poor bio-availability, delivery systems containing curcuminoids were developed. We showed that isoforms and conjugates and newly developed delivery systems of curcumin bind amyloid plaques and CAA and show comparable fluorescent properties as curcumin. For diagnostic studies this implies that all contents of newly developed delivery systems, including curcumin, DMC an BDMC and secondary formed curcumin conjugates harbor amyloid binding properties and could yield diagnostic purpose. Newly developed delivery systems, e.g. micelles, solid lipid nanoparticles and liposomes, did not show to affect amyloid binding properties. Similar binding properties could also indicate a therapeutic role of isoforms and conjugates. Previous studies showed that curcumin reverses existing amyloid pathology and associated neurotoxicity in a mouse model [9, 53]. If conjugates harbor the same functional effects on amyloid formation and related neurotoxicity is unknown. More research is therefore needed to assess possible functional effects of isoforms and conjugates on AD pathology.

Strengths of our study are the well-described patient cohort including various neurodegenerative features, thorough assessment of different curcumin forms and comparison with commonly used neuropathological IHC. Our patient cohort consists of a fair amount of well described AD-cases, cases with other neurodegenerative conditions as well as healthy controls, while previous studies assessed binding properties of curcumin mostly in animal models. Applying commonly used neuropathological IHC-staining we directly compared curcumin with established staining methods, which allows assessment of its specificity towards pathological structures. A limitation of our study is that the use of high concentrations curcumin in post mortem staining might not reflect concentrations that could be reached in-vivo. Although turmeric, with a mass percentage of only ≈3% curcuminoids, showed similar staining patterns and intensity as pure curcumin it should be noted that clinically reached concentrations might be unable to effectively bind pathology. Future studies might therefore test the minimal concentration needed to label pathology.

Secondly, we tested a wide variety of curcumin forms, however not synthesized forms of curcumin (e.g. CRANAD-28). CRANAD-28 might have amyloid plaques and CAA binding properties and beneficial blood brain barrier penetration, yet is not applicable for human use [54]. Lastly, as we focused on isoforms and conjugates representing the majority of circulating curcumin we did not test reduced forms of curcumin. Future studies might test binding properties of synthesized and reduced forms of curcumin.

The retina, as a protrusion of the central nervous system, might reflect neurodegenerative disease and is therefore of interest as a target for in-vivo fluorescent imaging both in ophthalmology and neurology. Previously, Cordeiro et al. visualized apoptotic cells in glaucoma patients with fluorescent imaging and showed a successful example of fluorescent molecular imaging in the retina [3]. Others claimed amyloid presence in both post mortem and in-vivo retinas of AD patients, visualized with curcumin [22–24]. This finding is controversial however, as other groups were unable to replicate post mortem detection of retinal amyloid [13, 46, 51]. Our results support the notion that, if fibrillar amyloid or amyloid angiopathy are present in the retina in AD,
curcuminoids might be used as labeling fluorophore for non-invasive fluorescent retinal imaging.

Conclusion
In conclusion, curcumin, its isoforms, conjugates and bio-available forms bind to fibrillar Aβ plaques and CAA, and faintly stain neurofibrillary tangles in post mortem AD brain tissue. They do not show binding in control brain or to specific structures observed in other neurodegenerative disease like FTLD and PD. As conjugates and bio-available curcumin forms show comparable binding properties, curcumin might be an interesting candidate for in-vivo diagnostics in AD like retinal fluorescent imaging.

Abbreviations
AD: Alzheimer’s disease; Aβ: Amyloid-beta; BDMC: Bis-demethoxycurcumin; BMC: Demethoxycurcumin; CAA: Cerebral amyloid angiopathy; CAA-1: Cerebral amyloid angiopathy type 1; CAA-2: Cerebral amyloid angiopathy type 2; CSF: Cerebrospinal fluid; DAB: 3,3′-diaminobenzidine; DAP: 4′-diamidino-2-phenylindole; DLB: Dementia with Lewy bodies; LOAD: Early onset Alzheimer’s disease; FTLD: Frontotemporal lobar degeneration; IHC: Immunohistochemistry; LOAD: Late onset Alzheimer’s disease; MRI: Magnetic resonance imaging; NBB: The Netherlands Brain Bank; NFTs: Neurofibrillary tangles; PART: Primary age-related tauopathy; PBS: Phosphate-buffered saline; PD: Parkinson’s disease; PET: Positron emission tomography; PI: D: Pick’s disease; PM: Post mortem delay; pTau: Phosphorylated tau; TBS: Tris-buffered saline; TDP-43: TAR DNA-binding protein 43

Acknowledgements
Anti-amyloid beta antibody (IC-16) was kindly provided by Carsten Korth, Heinrich Heine University, Dusseldorf, Germany.

Funding
This research was funded by Alzheimer Nederland.

Authors’ contributions
JdH designed the study and experiments, performed analysis, prepared figures and drafted the manuscript. TM designed experiments, performed the experiments and performed analysis. JH performed analysis and supervised the study. FH designed and supervised the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Prior to death, donors signed informed consent with the Netherlands Brain Bank (NBB) for brain autopsy and use of brain tissue and medical records for research purposes.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 21 June 2018 Accepted: 27 July 2018
Published online: 09 August 2018

References
1. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–401. https://doi.org/10.1007/s00401-006-0127-z
2. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
3. Cordeiro MF, Normando EM, Cardoso MJ, Miodragovic S, Jeylani S, Davis BM, Guo L, Ourselin S, A’Hem R, Bloom PA (2017) Real-time imaging of single neuronal cell apoptosis in patients with glaucoma. Brain 140:1757–1767. https://doi.org/10.1093/brain/awx088
4. Cummings JL (2004) Alzheimer’s disease. N Engl J Med 351:56–67. https://doi.org/10.1056/NEJMra0402023
5. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumannakara AB, Abbruzzese JL, Ng CS, Badmave V, Kurzrock R (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491–4499. https://doi.org/10.1158/1078-0432.CCR-08-0024
6. Dickson TC, Vickers JC (2001) The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience 105:99–107
7. Dutzmann S, Schiborr C, Kocher A, Platus U, Hattingen J, Gessler F, Quick-Weller J, Franz K, Seifert V et al (2016) Intratumoral concentrations and effects of orally administered micellar curcuminoids in glioblastoma patients. Nutr Cancer 68:943–948. https://doi.org/10.1080/01635383.2016.1187281
8. Duyckaerts C, Braak H, Bidan JP, Buek L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M et al (2015) PART is part of Alzheimer disease. Acta Neuropathol 129:749–756. https://doi.org/10.1007/s00401-015-1390-7
9. Garcia-Alloza M, Borelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095–1104. https://doi.org/10.1111/j.1471-4159.2007.04613.x
10. Goel A, Kunnumannakara AB, Aggarwal BB (2008) Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol 75:787–809. https://doi.org/10.1016/j.bcp.2007.08.016
11. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG (2010) Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58:2095–2099. https://doi.org/10.1021/jf9024807
12. Heger M, van Golen RF, Broekgaarden M, Michel MC (2014) The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev 66:222–307. https://doi.org/10.1121/10.004044
13. Ho CY, Troncoso JC, Knox D, Hattingen J, Gessler F, Quick-Weller J, Franz K, Seifert V et al (2016) Intratumoral concentrations and effects of orally administered micellar curcuminoids in glioblastoma patients. Nutr Cancer 68:943–948. https://doi.org/10.1080/01635383.2016.1187281
14. Holder GM, Plummer JL, Ryan AJ (1978) The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8:761–768
15. Hooper C, Lovestone S, Sainz-Fuertes R (2008) Alzheimer’s disease. N Engl J Med 351:56–67. https://doi.org/10.1056/NEJMra0402023
16. Jellinger KA, Alafuzoff I, Attenuates J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Earle HD, Erkinjuntti T et al (2015) PART is part of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–401. https://doi.org/10.1007/s00401-006-0127-z
17. Jellinger KA, Alafuzoff I, Attenuates J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Hof PR, Hyman BT, Jack CR Jr et al (2015) PART is part of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–401. https://doi.org/10.1007/s00401-006-0127-z
18. Jellinger KA, Alafuzoff I, Attenuates J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Hof PR, Hyman BT, Jack CR Jr et al (2015) PART is part of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–401. https://doi.org/10.1007/s00401-006-0127-z
19. Jellinger KA, Alafuzoff I, Attenuates J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Hof PR, Hyman BT, Jack CR Jr et al (2015) PART is part of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–401. https://doi.org/10.1007/s00401-006-0127-z
20. Kanai M, Imaiizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T (2012) Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer
28. Maiti P, Dunbar GL (2018) Use of curcumin, a natural polyphenol for...
29. Maiti P, Hall TC, Paladugu L, Kolli N, Learman C, Rossignol J, Dunbar GL
30. Maiti P, Paladugu L, Dunbar GL (2018) Solid lipid curcumin particles provide...
31. Marczylo TH, Steward WP, Gescher AJ (2009) Rapid analysis of curcumin and...
32. Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs...
33. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH,
34. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Cantalupo R,...
35. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH,
36. Maiti P, Dunbar GL (2018) Use of curcumin, a natural polyphenol for...
37. Mondal S, Ghosh S, Moulik SP (2016) Stability of curcumin in different
38. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW,
39. Mutsuga M, Chambers JK, Uchida K, Tei M, Makubuchi T, Mizorogi T,
40. Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Taumii E, Hashimoto T,
41. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent anti-
42. Pan MH, Huang TM, Lin JK (1999) Biotransformation of curcumin through...
43. Ravindranath V, Chandrasekharan N (1981) Metabolism of curcumin–studies with∗∗∗curcumin. Toxicology 22:337–344
44. Sasaki H, Sunagawa Y, Takahashi K, Imazumi A, Fukushima H, Hashimoto T,
45. Sclabber C, Kocher A, Behnam D, Jandasek L, Toelstede S, Frank J (2014) The
46. McCarron M, Minett T, Matthews F et al (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J
47. Marshall J, Fuchs DT, Ashfaq A et al (2017) Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight 2: Doi https://doi.org/10.1172/JCI.insight.93621
48. Maiti P, Dunbar GL (2018) Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci. 19. https://doi.org/10.3390/ijms19061637
49. Maiti P, Hall TC, Paladugu L, Kolli N, Learman C, Rossignol J, Dunbar GL (2016) A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5x-familial Alzheimer’s disease mice. Histochern Cell Biol 146:609–625. https://doi.org/10.1007/s00418-016-1464-1
50. Maiti P, Paladugu L, Dunbar GL (2018) Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the SxFAD mouse model of Alzheimer’s disease. BMC Neurosci 19; 750. https://doi.org/10.1186/s12888-018-0046-3
51. Marczylo TH, Steward WP, Gescher AJ (2009) Rapid analysis of curcumin and curcumin metabolites in rat biotissues using a novel ultraperformance liquid chromatography (UPLC) method. J Agric Food Chem 57:797–803. https://doi.org/10.1021/jf803038f
52. Marczylo TH, Verschoyle RD, Cooke DN, Monzoroni P, Steward WP, Gescher AJ (2007) Comparison of��统 availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60:171–177. https://doi.org/10.1007/s00280-006-0355-x
53. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 89:388–100. https://doi.org/10.1212/WNL.0000000000004580
54. McKeith IG, Galasko D, Kosaak K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mima SS, Byrne EJ et al (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124
55. McFann GM, Knopman DS, Cherlow K, Hyman BT, Jack CR, Kavas CH, Klunk WE, Koresheit WJ, Manly JJ, Mayeux R et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005
56. Mohorko N, Repovi G, Popovic M, Kovacs GG, Brescianac M (2010) Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples.